ACADIA to Host Conference Call and Webcast on Tuesday, August 5,
2014, at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—Jul. 29, 2014—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today announced that it will report its
unaudited financial results for the second quarter ended June 30, 2014
on Tuesday, August 5, 2014, after the U.S. financial markets close.
ACADIA's management will host a conference call and webcast on Tuesday,
August 5, 2014, at 5:00 p.m. Eastern Time to discuss ACADIA’s financial
results and development programs.
The conference call may be accessed by dialing 866-578-5771 for
participants in the United States or Canada and 617-213-8055 for
international callers (reference passcode 94851179). A telephone replay
of the conference call may be accessed through August 19, 2014 by
dialing 888-286-8010 for callers in the United States or Canada and
617-801-6888 for international callers (reference passcode 56603137).
The conference call also will be webcast live on ACADIA’s website, www.acadia-pharm.com,
under the investors section and will be archived there until August 19,
2014.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines that address unmet medical
needs in neurological and related central nervous system disorders.
ACADIA has a pipeline of product candidates led by pimavanserin, for
which we have reported positive Phase III trial results in Parkinson’s
disease psychosis and which has the potential to be the first drug
approved in the United States for this disorder. We are currently
completing NDA-enabling clinical and manufacturing activities for
pimavanserin and are planning to submit an NDA with the FDA near the end
of 2014. Pimavanserin is also in Phase II development for Alzheimer’s
disease psychosis and has successfully completed a Phase II trial in
schizophrenia. ACADIA also has clinical-stage programs for chronic pain
and glaucoma in collaboration with Allergan, Inc. and two preclinical
programs directed at Parkinson’s disease and other neurological
disorders. All product candidates are small molecules that emanate from
internal discoveries. ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the progress and timing of ACADIA’s
drug discovery and development programs, either alone or with a partner,
including clinical trials; the benefits to be derived from ACADIA’s
product candidates, in each case including pimavanserin; the potential
of pimavanserin to be the first drug approved in the United States for
Parkinson’s disease psychosis; and ACADIA’s plans to submit an NDA near
the end of 2014. These statements are only predictions based on current
information and expectations and involve a number of risks and
uncertainties. Actual events or results may differ materially from those
projected in any of such statements due to various factors, including
the risks and uncertainties inherent in drug discovery, development and
commercialization, and collaborations with others, and the fact that
past results of clinical trials may not be indicative of future trial
results. For a discussion of these and other factors, please refer to
ACADIA’s annual report on Form 10-K for the year ended December 31, 2013
as well as ACADIA’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. This
caution is made under the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. All forward-looking statements
are qualified in their entirety by this cautionary statement and ACADIA
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as
required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Steve Davis, Executive Vice
President,
Chief Financial Officer and Chief Business Officer
Lisa
Barthelemy, Director of Investor Relations
(858) 558-2871